You searched for "operation"
Can transcutaneous peroneal nerve stimulation treat OAB?
The peroneal nerve follows sacral, pudendal, and tibial nerves as a target for overactive bladder (OAB) treatment. This multicentre prospective randomised RCT compared a transcutaneous electrical neuromodulation system (eTNM) at-home treatment once daily for 30 minutes to solifenacin 5mg once...Our experience: from London and Glasgow urology, to the world down under
In November 2023, we were privileged to have been hosted at the Urological Society of Australia and New Zealand’s (USANZ) annual trainee week in the beautiful city of Adelaide, South Australia. Each year, USANZ organises a week for their local...Study confirms UroShield™ device extremely effective as a bacteriostatic agent
UroShield™ is a breakthrough disposable ultrasound device developed to prevent catheter blockages and biofilm formation, resulting in a reduction in Urinary Tract Infections (UTI) and therefore reducing the need for antibiotics, improving patient outcomes and lowering healthcare costs.
Urology patient assessment – importance of holistic approach – new paradigm
Mild cognitive impairment (MCI) seems to affect 30% of the general population above 65 and its presence has a wide range of significance. This is a prospective single centre study to look at MCI in adult urological patients above 18...The stonecutters of 17th Century London
In this series of articles I am going to show you some of the exhibits contained in the Museum of Urology, hosted on the BAUS website (www.baus.org.uk). In the last article I told you about the prostatic punch. If you...An update on lower pole stone management for 2015
Introduction Urolithiasis is an increasing healthcare problem, with an estimated lifetime prevalence of up to 15% [1]. The number of interventions undertaken for stone disease has increased dramatically over recent years, particularly with respect to ureteroscopy and percutaneous nephrolithotomy (PCNL)...
BCG after TURBT – does timing matter?
Intravesical bacille Calmette–Guerin (BCG) therapy continues to be widely used for patients with intermediate / high-risk non-muscle invasive bladder cancer (NMIBC). In this article, the researchers identified the lack of sufficient evidence with regards to timing of BCG after transurethral...
